Insights on CXC chemokine receptor 2 in breast cancer: An emerging target for oncotherapy.

Abstract

Breast cancer is the most common malignant neoplasm in women worldwide, and the treatment regimens currently available are far from optimal. Targeted therapy, based on molecular typing of breast cancer, is the most precise form of treatment, and CXC chemokine receptor 2 (CXCR2) is one of the molecular markers used in targeted therapies. As a member of the seven transmembrane G-protein-coupled receptor family, CXCR2 and its associated ligands have been increasingly implicated in tumor-associated processes. These processes include proliferation, angiogenesis, invasion, metastasis, chemoresistance, and stemness and phenotypic maintenance of cancer stem cells. Thus, the inhibition of CXCR2 or its downstream signaling pathways could significantly attenuate tumor progression. Therefore, studies on the biological functions of CXCR2 and its association with neoplasia may help improve the prognosis of breast cancer. Furthermore, the targeting of CXCR2 could supplement the present clinical approaches of breast cancer treatment strategies. The present review discusses the structures and mechanisms of CXCR2 and its ligands. Additionally, the contribution of CXCR2 to the development of breast cancer and its potential therapeutic benefits are also discussed.

• Authors: Fengzhu Guo, Lang Long, Jiantao Wang, Yuyi Wang, Yanyang Liu, Li Wang, Feng Luo
• Journal: Oncology letters (Oncol Lett) Vol. 18 Issue 6 Pg. 5699-5708 (Dec 2019) ISSN: 1792-1074 [Print] Greece
• PMID: 31788042 (Publication Type: Journal Article, Review)
• Copyright: Copyright: © Guo et al.